CRNX
Price
$31.93
Change
-$0.06 (-0.19%)
Updated
Jul 11 closing price
Capitalization
2.99B
27 days until earnings call
IONS
Price
$41.73
Change
-$0.65 (-1.53%)
Updated
Jul 11 closing price
Capitalization
6.64B
19 days until earnings call
Interact to see
Advertisement

CRNX vs IONS

Header iconCRNX vs IONS Comparison
Open Charts CRNX vs IONSBanner chart's image
Crinetics Pharmaceuticals
Price$31.93
Change-$0.06 (-0.19%)
Volume$598.28K
Capitalization2.99B
Ionis Pharmaceuticals
Price$41.73
Change-$0.65 (-1.53%)
Volume$1.55M
Capitalization6.64B
CRNX vs IONS Comparison Chart in %
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. IONS commentary
Jul 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Hold and IONS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 12, 2025
Stock price -- (CRNX: $31.93 vs. IONS: $41.73)
Brand notoriety: CRNX and IONS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 79% vs. IONS: 92%
Market capitalization -- CRNX: $2.99B vs. IONS: $6.64B
CRNX [@Biotechnology] is valued at $2.99B. IONS’s [@Biotechnology] market capitalization is $6.64B. The market cap for tickers in the [@Biotechnology] industry ranges from $318.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileIONS’s FA Score has 0 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • IONS’s FA Score: 0 green, 5 red.
According to our system of comparison, IONS is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 5 TA indicator(s) are bullish while IONS’s TA Score has 4 bullish TA indicator(s).

  • CRNX’s TA Score: 5 bullish, 5 bearish.
  • IONS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CRNX and IONS are a good buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а +7.15% price change this week, while IONS (@Biotechnology) price change was -2.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.14%. For the same industry, the average monthly price growth was +16.46%, and the average quarterly price growth was +20.75%.

Reported Earning Dates

CRNX is expected to report earnings on Nov 06, 2025.

IONS is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+9.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IONS($6.64B) has a higher market cap than CRNX($2.99B). IONS YTD gains are higher at: 19.365 vs. CRNX (-37.551). IONS (-357.21M) and CRNX (-373.49M) have comparable annual earnings (EBITDA) . IONS has more cash in the bank: 2.15B vs. CRNX (1.27B). CRNX has less debt than IONS: CRNX (50.8M) vs IONS (1.41B). IONS has higher revenues than CRNX: IONS (717M) vs CRNX (760K).
CRNXIONSCRNX / IONS
Capitalization2.99B6.64B45%
EBITDA-373.49M-357.21M105%
Gain YTD-37.55119.365-194%
P/E RatioN/AN/A-
Revenue760K717M0%
Total Cash1.27B2.15B59%
Total Debt50.8M1.41B4%
FUNDAMENTALS RATINGS
CRNX vs IONS: Fundamental Ratings
CRNX
IONS
OUTLOOK RATING
1..100
5174
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
67100
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
6341
P/E GROWTH RATING
1..100
10067
SEASONALITY SCORE
1..100
n/a42

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRNX's Valuation (92) in the Pharmaceuticals Major industry is in the same range as IONS (96) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IONS’s over the last 12 months.

CRNX's Profit vs Risk Rating (67) in the Pharmaceuticals Major industry is somewhat better than the same rating for IONS (100) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than IONS’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as IONS (98) in the Biotechnology industry. This means that CRNX’s stock grew similarly to IONS’s over the last 12 months.

IONS's Price Growth Rating (41) in the Biotechnology industry is in the same range as CRNX (63) in the Pharmaceuticals Major industry. This means that IONS’s stock grew similarly to CRNX’s over the last 12 months.

IONS's P/E Growth Rating (67) in the Biotechnology industry is somewhat better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that IONS’s stock grew somewhat faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXIONS
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
Bearish Trend 1 day ago
68%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
68%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
70%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 10 days ago
62%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
71%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
74%
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
Bullish Trend 1 day ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IONS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IFUTX27.60N/A
N/A
Invesco Dividend Income R6
VYRBX26.34N/A
N/A
VY® Baron Growth R6
DCGTX18.60N/A
N/A
Jackson Square SMID-Cap Growth IS
CAFAX43.78-0.18
-0.41%
American Funds AMCAP 529A
EPLIX22.24-0.13
-0.58%
NYLI Epoch U.S. Equity Yield Inv Class

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-0.19%
XNCR - CRNX
61%
Loosely correlated
-4.85%
TRDA - CRNX
57%
Loosely correlated
-3.11%
IDYA - CRNX
57%
Loosely correlated
-1.40%
RVMD - CRNX
56%
Loosely correlated
-1.25%
KRYS - CRNX
56%
Loosely correlated
-1.05%
More

IONS and

Correlation & Price change

A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ALNY. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IONS
1D Price
Change %
IONS100%
-1.53%
ALNY - IONS
54%
Loosely correlated
-1.85%
IDYA - IONS
52%
Loosely correlated
-1.40%
XENE - IONS
50%
Loosely correlated
-2.33%
BEAM - IONS
49%
Loosely correlated
-3.95%
CRNX - IONS
48%
Loosely correlated
-0.19%
More